In addition, JQ1 treatment showed a synergistic association in inducing apoptosis of the ibrutinib-resistant MCL cells when combined with another agent such as ibrutinib or panobinostat (pan-histone deacetylase inhibitor) or palbociclib (CDK4/6 inhibitor) or ABT-199 [160]. The gene discussed is CDK4; the disease is mantle cell lymphoma.